Tectorigenin, a natural product isolated and purified from the rhizomes of Belamcanda chinensis (L.) DC., has antioxidant, anti-inflammatory by inhibiting the induction of COX-2 in the inflammatory cells activities and may be a possible therapeutic agent for leukemia.
Tectorigenin/鸢尾黄素 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Mouse islet cells
40 μg/ml
24 hours
Promote PDX1 expression
J Biol Chem. 2020 Sep 11;295(37):12975-12992
Bone marrow mononuclear (BMM) cells
0, 10, 40, 80 µM
1 hour
To evaluate the effect of Tectorigenin on RANKL-induced NF-κB signaling activation, results showed that Tectorigenin significantly reduced phosphorylation levels of NF-κB p65 and IκBα.
J Cell Mol Med. 2018 Oct;22(10):5121-5131
Rat tendon-derived stem cells (TDSCs)
50 and 100 µM
1-hour pretreatment followed by 24-hours co-culture withours TNF-α
To evaluate the inhibitory effects of Tectorigenin on TNF-α-induced inflammation, apoptosis, and ossification in TDSCs. Results showed Tectorigenin suppressed TNF-α-induced upregulation of MMP-3/9/13, COX-2, iNOS, and IL-6 while increasing collagen I and IL-10 expression.
Front Cell Dev Biol. 2020 Oct 22;8:568894
PA-induced IR C2C12 cells
10 µg/mL
24 hours
TG partially restores GLUT4 levels and improves insulin sensitivity in IR C2C12 cells
Int J Biol Sci. 2023 Mar 5;19(5):1579-1596
C2C12 cells
10 µg/mL
24 hours
TG enhances GLUT4 expression and promotes glucose uptake
Int J Biol Sci. 2023 Mar 5;19(5):1579-1596
LO2 cells
1–200 µM
24 hours
To evaluate the effect of Tectorigenin on the viability of LO2 cells, results showed no significant effect on cell viability at concentrations of 1–200 μM
Phytother Res. 2019 Apr;33(4):1055-1064
RAW 264.7 cells
1–100 µM
24 hours
To evaluate the effect of Tectorigenin on the viability of RAW 264.7 cells, results showed no significant effect on cell viability at concentrations of 1–100 μM
Phytother Res. 2019 Apr;33(4):1055-1064
HaCaT human epidermal keratinocytes
0.1, 1, 10 µM
24 hours
Tectorigenin significantly reduced MMP-1 levels and increased type 1 collagen levels, thereby preventing collagen degradation.
Nutrients. 2018 Dec 17;10(12):1998
HaCaT human epidermal keratinocytes
1, 10 µM
24 hours
Tectorigenin significantly inhibited UV-B-induced expression of apoptosis-related proteins such as caspase-3 and Bax, and increased Bcl-2 protein levels.
Nutrients. 2018 Dec 17;10(12):1998
HaCaT human epidermal keratinocytes
1, 10 µM
24 hours
Tectorigenin significantly increased the expression of anti-oxidative enzymes such as catalase and glutathione.
Tectorigenin at concentrations between 0.1 and 10 µM was not toxic for HaCaT cells and significantly inhibited UV-B-induced cell death.
Nutrients. 2018 Dec 17;10(12):1998
RIN-m5F cells
40 μg/ml
24 hours
Promote PDX1 expression
J Biol Chem. 2020 Sep 11;295(37):12975-12992
INS-1 cells
40 μg/ml
24 hours
Promote PDX1 expression and activate ERK signaling pathway
J Biol Chem. 2020 Sep 11;295(37):12975-12992
Human liver microsomes
100 µM
30 minutes
Investigate the glucuronidation metabolism of Tectorigenin, one metabolite M was detected
Molecules. 2022 Jun 26;27(13):4104
RAW264.7 cells
0, 10, 40, 80 µM
4 days
To evaluate the preventive effect of Tectorigenin on RANKL-induced osteoclast differentiation, results showed that Tectorigenin reduced osteoclast differentiation in a dose-dependent manner.
J Cell Mol Med. 2018 Oct;22(10):5121-5131
Bone marrow mononuclear (BMM) cells
0, 10, 40, 80 µM
4 days
To evaluate the preventive effect of Tectorigenin on RANKL-induced osteoclast differentiation, results showed that Tectorigenin reduced osteoclast differentiation in a dose-dependent manner.
J Cell Mol Med. 2018 Oct;22(10):5121-5131
RAW264.7 cells
0, 10, 40, 80 µM
48 hours
To evaluate the effect of Tectorigenin on RANKL-stimulated osteoclast-specific gene expression, results showed that Tectorigenin down-regulated the expression of TRAP, NFATc1, Cts K, and MMP9.
J Cell Mol Med. 2018 Oct;22(10):5121-5131
Bone marrow mononuclear (BMM) cells
0, 10, 40, 80 µM
48 hours
To evaluate the effect of Tectorigenin on RANKL-stimulated osteoclast-specific gene expression, results showed that Tectorigenin down-regulated the expression of TRAP, NFATc1, Cts K, and MMP9.
J Cell Mol Med. 2018 Oct;22(10):5121-5131
RAW264.7 cells
0, 10, 40, 80 µM
6 hours
To evaluate the effect of Tectorigenin on RANKL-induced NF-κB transcriptional activity, results showed that Tectorigenin reduced NF-κB transcriptional activity in a dose-dependent manner.
J Cell Mol Med. 2018 Oct;22(10):5121-5131
Tectorigenin/鸢尾黄素 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice
Ovariectomy-induced osteoporosis model
Abdominal injection
1 mg/kg and 10 mg/kg
Every 3 days for 6 weeks
To evaluate the effect of Tectorigenin on ovariectomy-induced bone loss, results showed that Tectorigenin significantly reduced bone loss and improved bone microstructure.
J Cell Mol Med. 2018 Oct;22(10):5121-5131
C57BL/6J mice
HFHSD-induced T2DM mouse model
Intraperitoneal injection
10, 20, 40 mg/kg
Every other day for 1-2 months
Both prophylactic and therapeutic uses of TG significantly ameliorate insulin resistance and hyperglycemia in T2DM mice
Int J Biol Sci. 2023 Mar 5;19(5):1579-1596
C57BL/6J mice
High-fat/high-sucrose diet-induced diabetes model
Intraperitoneal injection
10, 20, 40 mg/kg
Once every 2 days for 1 month (treatment) or 3 months (prevention)
Ameliorate hyperglycemia and glucose intolerance, inhibit ER stress and islet β-cell apoptosis
J Biol Chem. 2020 Sep 11;295(37):12975-12992
Sprague-Dawley rats
Achilles tenotomy-induced tendinopathy model
Local injection (area between Achilles tendon and skin)
100 μM
Once weekly for 8 weeks
To assess the therapeutic effect of Tectorigenin on rat tendinopathy. Results demonstrated Tectorigenin improved disordered collagen fiber arrangement, reduced calcification, and decreased MMP-3/13 expression in tendon tissues.
Front Cell Dev Biol. 2020 Oct 22;8:568894
C57BL/6J mice
LPS/D-GalN-induced fulminant hepatic failure model
Intraperitoneal injection
12.5, 25, 50 mg/kg
Single dose, observed for 24 hours
To evaluate the protective effect of Tectorigenin on LPS/D-GalN-induced fulminant hepatic failure, results showed Tec significantly reduced serum ALT and AST levels, histological injury, apoptosis, and mortality, and suppressed the production of inflammatory cytokines such as TNF-α and IL-6
搜索
